Results 1 - 10 of 217 : 1 2 3 4 5 6 7 8 9 Next
Why I'm Buying Emerging Markets
They're cheaper, growing faster, and their problems are mostly cyclical, not structural.
Abraxis Fires AstraZeneca, Gets Fired Up
Finally!
The company lays out its pipeline for investors to digest.
The biotech had everything to lose and almost nothing to gain with its recent clinical trial.
AstraZeneca is trying to revive Iressa.
The drugmaker settles a few patent disputes with generic-drugmaker nemeses.
Double Trouble for AstraZeneca
Generic woes and a miscue in the pipeline, oh my.
The Little Chemotherapy That Could
Slow and steady isn't very exciting.
The Market Indicator You Shouldn't Ignore
There's a silver lining in the market's recent slump.
Pfizer Takes the Plunge Into Stem-Cell Research
It looks like a new unit focusing on this will include work with other companies.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK